Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients (Q34661651)

3 August 2017

Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients (English)

1 reference

3 August 2017

0 references

0 references

0 references

3

Christoph U Correll

1 reference

3 August 2017

Jimmi Nielsen

1

1 reference

3 August 2017

Søren Skadhede

series ordinal

2

1 reference

3 August 2017

language of work or name

English

0 references

publication date

2 June 2010

1 reference

3 August 2017

Neuropsychopharmacology

1 reference

3 August 2017

35

1 reference

3 August 2017

1997-2004

1 reference

3 August 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1038/npp.2010.78

3 August 2017

0 references

cites work

Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

Validity of the diagnosis of a single depressive episode in a case register

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

Which comes first: atypical antipsychotic treatment or cardiometabolic risk?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

The metabolic syndrome and schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

7 July 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

7 July 2018

https://api.crossref.org/works/10.1038%2FNPP.2010.78

Suicide risk in relation to psychiatric hospitalization: evidence based on longitudinal registers

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

Physical health monitoring of patients with schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

Consensus development conference on antipsychotic drugs and obesity and diabetes

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

Lifetime Risk for Diabetes Mellitus in the United States

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

Evidence of a dose-response relationship between urbanicity during upbringing and schizophrenia risk

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

Exposure to influenza epidemics during gestation and adult schizophrenia. A 40-year study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

Course of illness in a sample of 265 patients with first-episode psychosis--five-year follow-up of the Danish OPUS trial.

7 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.78

Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.78

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.78

Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.78

Family history of psychiatric illness as a risk factor for schizoaffective disorder: a Danish register-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.78

The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.78

Energy expenditure and physical activity in clozapine use: implications for weight management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.78

The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.78

Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

Psychiatrists' attitude towards and knowledge of clozapine treatment

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

The Danish Psychiatric Central Register.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055629

Reversibility of antipsychotic treatment-related diabetes in patients with schizophrenia: a case series of switching to aripiprazole

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20520598

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20520598

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NPP.2010.78

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference

3 August 2017

1 reference